These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2840219)

  • 21. Evaluation of the new control methods for oral poliomyelitis vaccine.
    Grachev VP; Karganova GG; Rumyantsev AA; Ivanova OE; Eremeeva TP; Drozdov SG
    Dev Biol (Basel); 2001; 105():211-7. PubMed ID: 11763330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
    Furesz J
    Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation and reversion of the Sabin vaccine strains of poliovirus.
    Minor PD
    Dev Biol Stand; 1993; 78():17-26. PubMed ID: 8388828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential use of new poliomyelitis vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1990; 68(5):545-8. PubMed ID: 1963117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Sep; 58(36):1002-6. PubMed ID: 19763076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WHO Working Group discussion on revision of the WHO recommendations for the production and control of poliomyelitis vaccines (oral): TRS Nos. 904 and 910. Report of Meeting held on 20-22 July 2010, Geneva, Switzerland.
    Martin J; Milne C; Minor P; Chumakov K; Baca-Estrada M; Caruana JF; Zhou T;
    Vaccine; 2011 Sep; 29(38):6432-6. PubMed ID: 21729731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria.
    Korsun N; Kojouharova M; Vladimirova N; Fiore L; Litvinenko I; Buttinelli G; Fiore S; Voynova-Georgieva V; Mladenova Z; Georgieva D
    J Med Virol; 2009 Sep; 81(9):1661-7. PubMed ID: 19626606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].
    Delpeyroux F; Guillot S; Szendröi A; Balanant J; Caro V; Cuervo N; Chevaliez S; Dahourou G; Crainic R
    Bull Soc Pathol Exot; 2000 Jul; 93(3):193-7. PubMed ID: 11030056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.
    Tebbens RJ; Pallansch MA; Kew OM; Cáceres VM; Jafari H; Cochi SL; Sutter RW; Aylward RB; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1471-505. PubMed ID: 17184393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.
    Combiescu M; Guillot S; Persu A; Baicus A; Pitigoi D; Balanant J; Oprisan G; Crainic R; Delpeyroux F; Aubert-Combiescu A
    Arch Virol; 2007; 152(4):727-38. PubMed ID: 17195957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus--Philippines, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Oct; 50(40):874-5. PubMed ID: 11666115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polio vaccines and the cessation of vaccination.
    Minor PD
    Expert Rev Vaccines; 2003 Feb; 2(1):99-104. PubMed ID: 12901601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poliomyelitis and the control programme.
    Basu RN
    Indian J Public Health; 1985; 29(3):157-61. PubMed ID: 3835132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
    Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
    Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.